27.07.2011 • News

Biogen Idec Posts Q2 Profit Of $288 Million

Biogen Idec posted second-quarter net income attributable to the company of $288.03 million or $1.18 per share compared to $293.44 million or $1.12 per share last year.

Non-GAAP net income attributable to the company was $332.2 million or $1.36 per share versus $343.2 million or $1.31 per share a year ago.
Quarterly revenues stood flat at $1.21 billion.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.37 per share on revenues of $1.18 billion for the quarter. Analysts' estimates typically exclude special items.

Going ahead, the company revised outlook for 2011. The company now expects earnings per share to be above $4.91. Non-GAAP earnings per share is expected to be above $5.70. Analysts expect earnings of $5.85 per share for the year.

Also, for 2011, revenue growth is expected to be in the low to mid-single digits versus 2010. Analysts anticipate revenues of $4.83 billion for the year.

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.